What is COEP's current stock price?

COEP (Coeptis Therapeutics, Inc.) is currently trading at $16.40 with a market cap of $57.6M.

What sector is Coeptis Therapeutics, Inc. in?

Coeptis Therapeutics, Inc. (COEP) operates in the Healthcare sector, specifically in the Biotechnology industry.

InvestLog

COEP Coeptis Therapeutics, Inc.

Healthcare

$16.40+0.00%ClosedMarket Cap: $57.6M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

5.76

P/S

40.76

EV/EBITDA

-4.83

DCF Value

$3.31

FCF Yield

-13.9%

Div Yield

0.0%

Margins & Returns

Gross Margin

87.2%

Operating Margin

-912.4%

Net Margin

-839.7%

ROE

-89.6%

ROA

-60.0%

ROIC

-71.4%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$113.8K	$-4.0M	$—
Q4 null	$862.0K	$-1.6M	$—
FY null	$1.4M	$-11.9M	$—
Q3 null	$237.4K	$-2.7M	$—

Analyst Ratings

View All

Consensus

Hold

Target (Consensus)

$—

Target (Median)

$—

Target Range

$— - $—

0 Strong Buy0 Buy1 Hold0 Sell0 Strong Sell

Trading Activity

Insider Trades

View All

BSG Series CM, LLC10 percent owner

SellMon May 04

Mehalick Daviddirector, 10 percent owner, officer: CEO and President

SellFri Feb 13

Mehalick Daviddirector, 10 percent owner, officer: CEO and President

SellFri Feb 13

Deschamps Philippedirector

SellFri Feb 13

Deschamps Philippedirector

SellFri Feb 13

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

-0.43

Coeptis Therapeutics, Inc., a biopharmaceutical company, develops and commercializes generic and branded pharmaceutical products and cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a Vy-Gen drug product for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; and CD38-Diagnostic, an in vitro screening tool to provide the ability to pre-determine which cancer patients are most likely to benefit from targeted anti-CD38 monoclonal antibodies therapies. The company has collaboration with Statera BioPharma to develop and commercialize STAT-201 for Crohn's disease; and Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. Coeptis Therapeutics, Inc. was founded in 2017 and is headquartered in Wexford, Pennsylvania.

Peers

CUE